Jack Greenwood, MD
Neurology with Special Qualifications in Child Neurology · Port Jefferson, NYNPI 1851396865
Payments from drug & device makers
Across 54 payments — averaging $19.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$291
- UCB, Inc.$165
- Supernus Pharmaceuticals, Inc.$120
- Ironshore Pharmaceuticals Inc.$95
- Biogen$91
- Takeda Pharmaceuticals U.S.A., Inc.$77
- plus $224 from 7 others
What the payments were for
- Speaking & faculty fees$626%
- Food & beverage$1,00294%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 8 | $291 |
| UCB, Inc. | 10 | $165 |
| Supernus Pharmaceuticals, Inc. | 7 | $120 |
| Ironshore Pharmaceuticals Inc. | 5 | $95 |
| Biogen | 5 | $91 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $77 |
| Acorda Therapeutics, Inc | 3 | $62 |
| Sunovion Pharmaceuticals Inc. | 3 | $60 |
| Shire North American Group Inc | 2 | $32 |
| Amneal Pharmaceuticals LLC | 1 | $23 |
| AstraZeneca | 1 | $19 |
| Vertical Pharmaceuticals, LLC | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QULIPTA$122
How this compares
$1,064 in reported general payments places this provider in the 45th percentile of 161 neurology with special qualifications in child neurology providers in New York.
See all neurology with special qualifications in child neurology providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Avonex Pen (4 Pack)Interferon Beta-1a | 13 | $97,029 |
| DilantinPhenytoin Sodium Extended | 12 | $4,966 |
| Lacosamide | 24 | $3,691 |
| Gabapentin | 40 | $764 |
| Donepezil Hcl | 54 | $466 |
| Topiramate | 30 | $235 |
| Primidone | 13 | $163 |
| Amitriptyline Hcl | 11 | $155 |
| Levetiracetam | 14 | $136 |
Paid to pharmacies, not to this prescriber.
Other neurology with special qualifications in child neurology in Port Jefferson
- Claudia ChiribogaNew York$8.5M
- Darryl DevivoNew York$1.9M
- Heather LauNew York$1.7M
- Eric SegalN White Plains$1.7M
- Devorah SegalNew York$1.6M
- Jennifer BainNew York$1.4M
- Robert FryerNew York$730K
- Klaus WernerSyracuse$703K
- Mohammad QasaymehAmherst$463K
- Nicolas AbreuNew York$423K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.